STAT Plus: Wegovy and Zepbound get primetime treatment
The Readout
Your guide to what’s new in biotech. Sign up for the newsletter here.
Latest
Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast
STAT Plus: Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots
STAT Plus: The first vaccine for the increasingly prevalent chikungunya virus is here
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga
All Coverage
advertisement